



**phlaxis**  
Food allergies. Solved.



**FOOD ALLERGIES:**

**AN EPIDEMIC,  
OVERLOOKED**



**32 MILLION**  
Americans affected




**EVERY 3 MINUTES**  
an ER admission



**1.855 million**  
children with peanut  
allergy



Only **20%** of  
patients outgrow  
peanut allergy



**\$25 BILLION**  
spent managing pediatric  
food allergies

**MORE THAN JUST MEALS**

Children experience bullying and feel alienated


Parents prone to stress-induced ailments

Reduced quality of life for families



## AN INVERSE VACCINE

OUR SOLUTION:  
TREAT FOOD ALLERGIES  
WITH "VACCINE"



# OUR PLATFORM IS IN CLINICAL TRIAL

Celiac Disease



Multiple Sclerosis



IP in CeD and MS licensed to Anokion.

Food Allergy Therapy




Food Allergy Prevention  
(Ideation)




IP in food allergy still held by Jeff Hubbell and Melody Swartz,  
University of Chicago

# VALUE PROJECTION OF PLATFORM






# OUR SOLUTION: THERAPY




FIVE INSTANCES OF  
SENSITIZATION

TWO DOSES OF  
TREATMENT

FOOD  
CHALLENGE



- Our inverse vaccine are safer than allergen only on allergic mice
- Our inverse vaccine reduced Th2 cellular responses





WHAT MAKES US UNIQUE

# OUR VALUE PROPOSITIONS



CUSTOMIZABLE



LIMITED ADVERSE EVENTS



1-2 CLINICAL VISITS ONLY



SUSTAINED PROTECTION




FLEXIBILITY IN ADMINISTRATION



POTENTIAL APPLICATION TO PREVENTION

# POTENTIAL MARKET

6.6 million patients



Peanut allergy patients in the US  
(2% of the population)












4–17-year-old kids with peanut allergy  
(17% of all patients)

Estimated treatment: \$7,000


**Total Addressable Market: \$7.7 BILLION**




# EXISTING MARKET

	 <b>FDA-APPROVED</b>	 <b>PHASE III CLINICAL TRIALS</b>	 <b>OUR CANDIDATE VACCINE</b>
<b>EFFICACY</b>		 <i>(rejected in Phase III)</i>	
<b>SAFETY (adverse reactions)</b>			
<b>DURABILITY</b>		(NA)	
<b>DOSE</b>	<i>Continuous</i>	<i>Continuous</i>	<i>Few doses</i>


# PLATFORM APPLICATION



## R&D TIMELINE (Peanut Allergy Treatment)




# BUSINESS TIMELINE





# Opportunities for peanut allergy treatment startups

Our target phase for exit or partnering



# OUR TEAM




Jeffrey A. Hubbell

Ph.D.

Executive Chairman

Biomaterials and immune engineering expert with 75 patents and 5 startups, including one in immunological tolerance (Anokion) and another in food allergy (Clostrabio)



Shijie Cao

Ph.D.

Scientific lead

Expert in bioengineering and pharmaceutical sciences, with 20+ publications



Hikaru Ihara

M.D.

Business lead

Full-time MBA student at Booth School of Business, with experience in management consulting (McKinsey) and pharmaceutical (Eli Lilly)



Josette Chang

B.A. candidate

Intern

Undergraduate student in The College with experience in marketing, finance, and graphic design

# Funding- current and in the next 3 months



Food Allergy Fund  
**Secured \$100k**  
in Third Innovators Research Grant



NSF PFI-TT Grant

Award of up to **\$250k**

**(waiting result)**



New Venture Challenge



Award of up to **\$500k**



National Institute of  
Allergy and  
Infectious Diseases

NIH Research Project Grant  
Program (R01)

Award of up to **\$1.25M**

To submit: 7/5/2021



# Our Ask: Financing, Connection, and Advisory



**Financing**

**\$2 million for  
ongoing studies and  
CMC & Production**



**Connection**

**Key opinion leaders  
in primary care,  
allergy, pediatrics,  
dermatology**



**Advisory**

**Regulation, clinical  
trials, business  
(finance)**

## SUMMARY

- Our platform, patented by Hubbell's lab, is undergoing clinical trials
- We plan to apply this to a huge market of unmet need
- This platform is highly customizable to individual cases

# Q&A

# THANK YOU